IAMP EC Profiles (2016 – 2019)


Professor Detlev Ganten, M.D., Ph.D

Professor Ganten was born in Lüneburg in 1941. He studied medicine at the universities of Würzburg, Montpellier (France) and Tübingen. After taking his degree, he spent several years as a research scientist at the Clinical Research Institute in Montreal (Canada), and earned his Ph.D. at McGill University.
In 1975 Detlev Ganten was appointed Professor at the Department of Pharmacology at theUniversity of Heidelberg.
From 1991 to 2004 Professor Ganten was the founding director and president of the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch. He also was Director of the Department of Pharmacology at the Benjamin Franklin Medical Center of the Free University of Berlin.
From 2004 to 2008 Professor Ganten was Chief Executive Officer at the “Charité – Universitätsmedizin Berlin”, the joint medical faculty of the Free University and Humboldt University of Berlin.
Since 2005 Professor Ganten is the Chairman of the Foundation Board of the Charité Foundation. Since 2009 he is also Chairman of the joint Board of Trustees of the Max Planck Institute of Colloids and Interfaces and of the Max Planck Institute of Molecular Plant Physiology (Berlin-Potsdam), and he is President of the World Health Summit.
As a research scientist in the field of hypertension, Professor Ganten elucidated fundamental mechanisms of the pathophysiology and molecular biology of high blood pressure. His area of research includes the hormonal regulation of blood pressure, especially the renin-angiotensin system, and the molecular genetics of cardiovascular diseases and evolutionary medicine.

Professor Liu Depei

Prof. LIU Depei  is a medical molecular biologist. He graduated from Peking Union Medical College with a Ph.D. degree of biochemistry and molecular biology in 1986. During 1987-1990, he worked as a postdoctoral research fellow at the University of California, San Francisco in the United States. Now he is a professor and doctoral supervisor.
He served as President of Chinese Academy of Medical Sciences(CAMS) and Peking Union Medical College (PUMC) during the year of 2001-2011, and Vice President of Chinese academy of engineering(CAE) during the year of 2002-2010. He was elected the member of Chinese Academy of Engineering (CAE) in 1996, and the member of the U.S. Institute of Medicine (IOM) and the Third World Academy of Sciences (TWAS) in 2008. He is also the member of the eleventh and twelfth session of the Standing Committee of the National People’s Congress of China.
At the National Laboratory of Medical Molecular Biology, Dr. Liu has been engaged in researches on molecular biology about the regulation of gene expression, transgenic animals and disease models, gene transfer and gene therapy. In the studies of the regulation of hemoglobin gene expression and gene therapy for β-thalassemia, he discovered firstly erythrotic specific enhancer (HS2) of β-globin gene and its critical NFE 2/AP I site, discovered that erythrotic specific enhancers in different lengths enhance β-globin gene expression level in retrovirus vector mediated gene transfer, and established transgenic mouse models of β E and β41/42 genes. Dr. Liu also found that TC1 transposon inversion in high frequency in mammalian cells, proved Locus Control Region and proximal regulation elements corporately direct developmental regulation of β-globin gene cluster, created BAC mediated a/b-gene cluster and human apolipoprotein AI/CIII/AIV/AV gene cluster transgenic animal models, discovered that Myleran could enhance fetal γ-globin gene expression level apparently in adult anemic Rhesus monkeys and β-thalassemia patients, and completed β-globin gene site specific mutation by chimeric Due to his prominent work and achievements in scientific research and administrative management, Dr. Liu was awarded several times by the State Council, Ministry of Education, Ministry of Health of P. R. China and Beijing Municipal Government.



Academia Nacional de Medicina (Argentina) – coming soon

Accademia Nazionale dei Lincei, Italy 

Professor Mario Stefanini was born in Rome on November 10th 1939. He studied medicine at the universities of Pisa and Rome ‘La Sapienza’.  After taking his degree, he spent several years as a research scientist at the Institute of Medical Pathology  of the Sapienza University of Rome with Giuseppe A. Andres, and at the Department of Pathology of the University of California at Los Angeles (UCLA) with  Luciano Zamboni. In 1975 he was appointed professor of Histology and Embryology at the School of Medicine of the University of L’Aquila. From 1976 to 2010,  he was Professor at the Department of Histology and Medical Embryology of  the Sapienza University of Rome, and Head of the Department for several terms. He is now Senior Professor at the Sapienza University of Rome.
Dr Stefanini chaired the Sapienza University Ph. D. program on Cell Sciences and Technologies. He  has been member of the Scientific Research Committee and of the International Relationship Committee of the Sapienza University of Rome, the Board of the International Society for Developmental Biology (ISDB), the Executive Committee of the Inter Academy Medical Panel (IAMP) on behalf of the Accademia Nazionale dei Lincei, the Permanent Scientific Committee of the European Study Group for Molecular and Cellular Endocrinology of the Testis, the Committee for the School of Medicine of the Somalian National University,  the Addressing Committee of the Rome Foundation. He is currently President of the Medical  Academy of Rome, the National Committee for the Promotion of Italian Culture abroad of the Italian Department for Foreign Affairs, the Technical-Scientific Committee of the Rome Cancer Institute IFO-Regina Elena, the Health and Research Committee of the Rome Foundation. In 1998 he was elected member of the Accademia Nazionale dei Lincei.
As a research scientist in the field of Biology and Medicine of Reproduction he elucidated fundamental aspects  of the structural organization and functions of mammalian gametes and of the regulative mechanisms of mammalian gametogenesis. His research has characterized the ultrastructural aspects of gamete interactions at fertilization, has developed in vitro models to study the paracrine interactions among somatic and germ cells in the seminiferous epithelium and has visualized the presence and distribution of HIV in the testis and in ejaculated spermatozoa during HIV-1 infection. He is now studying the spermatogenesis and the biology of spermatogonial sperm cells in the rodents and in the human.
Dr Stefanini is author of over 100 original research articles. In 2005 he received the Premio Linceo for Biology awarded by the Accademia Nazionale dei Lincei.

Academy of Sciences, Malaysia

Academician Datuk Professor Dr Lai-Meng Looi is Malaysia’s inaugural National Distinguished Professor, positioned at  the Faculty of Medicine, University of Malaya (UM) in Kuala Lumpur.  She holds a concurrent appointment as senior consultant histopathologist at the University of Malaya Medical Centre (UMMC).    Professor Looi studied medicine as a Malaysian Federal Scholar at the University of Singapore (1970-1975), where she was a medalist in Pathology and Social Medicine, and won the King Edward VII Hall awards for literary works, art forms and poetry.  She trained in Surgical Pathology at UM, Royal Postgraduate Medical School (UK) and Brigham and Woman’s Hospital, Boston, (USA) and defended her research doctorate (on amyloidosis) at UM.  She assumed the Chair of Pathology, UM at the age of 36 years and during her long academic career at UM has served as Department Head, Deputy Dean (Postgraduate), Chair of the Medical Centre Research Committee, representative to the Malaysian Medical Council Chair and Chair of the Medical Advisory Committee of UMMC.  She continues to chair the Medical Research Ethics Committee/ Institutional Review Board and UM’s Committee for External Academic Evaluators (Science).  She has more than 190 peer-reviewed publications on amyloidosis, nephropathology and oncopathology, is devoted to promoting a research and ethical culture among researchers, has delivered >400 guest lectures and regularly conducts scientific writing workshops nationally and internationally.

Professor Looi is a Foundation Fellow and Academician of the Academy of Sciences Malaysia (ASM) and has served as Chief Censor and Scribe of the Academy of Medicine Malaysia.     She is Editor-in-Chief of the Malaysian Journal of Pathology, has served on the International Editorial Advisory Boards of Pathology, Journal of Pathology, Human Pathology and Histopathology, is Founding Vice-President of the Association of Malaysian Medical Journal Editors (AMMJE), and chairs the Ethics and Editorial Policies Committee of Asia-Pacific Association of Medical Editors (APAME).   A Fellow of both Royal Colleges of Pathologists, UK (RCPath) and Australasia (RCPA), she served as Examiner and Advisor to both.  She is the Founding President of the College of Pathologists, Academy of Medicine Malaysia, and was instrumental in developing pathology laboratory accreditation for Malaysia, the Pathology Act and several National guidelines on medical laboratory practices.  In 2010 she was honoured RCPA Distinguished Fellow and Inaugural National Distinguished Professor (Profesor Ulung Negara).  She co-chaired the InterAcademy Medical Panel (now the InterAcademy Partnership for Health) for two elected terms (2010-2016) and current represents ASM in its Executive Committee.   She was President of the World Association of Societies of Pathology and Laboratory Medicine (WASPaLM) from 2013-2016, and continues to Chair its Education Committee which focusses on capacity-building in countries-in-need.   In 2015, she was awarded the Gold-Headed Cane, the highest honour from WASPaLM, for outstanding leadership.  For her contributions to education and medical science, the King of Malaysia conferred her the Panglima Jasa Negara (PJN) with the title “Datuk” in 2011.  A recipient of the National Science Award and ASEAN Outstanding Scientist and Technologist Award, she was recently (August 2016) conferred the Merdeka Award 2016 (Health, Science and Technology category) for “outstanding contribution in pioneering research in amyloidosis, renal pathology and cancer pathology and for significant contributions and role in promoting the field of pathology in Malaysia and the region.”

Hassan II Academy of Science & Technology, Morocco – 

Rajae El Aouad is Professor of Immunology (School of Medicine and Pharmacy in Rabat) leaving in August 31, 2016 for the private sector as Director of Clinical Laboratory. She is Resident Member of the Hassan II Academy of Sciences and Technology (HIIAST) and a Member of the Steering Committee of the Royal Institute for Strategic Studies (IRES). She holds a Doctorate of Medical Studies, a Master of Sciences and a Master of Health Policy and Management. Rajae has held the positions of Vice-President for Research and Cooperation and Director of the Public Health School at the University Mohammed VIth for Health Sciences-Casablanca, Morocco (2014-2015), Director of the National  Institute of Hygiene -NIH-(2001-2012), and Chief of the Immunology and Virology  Department at the NIH (1987-2001 and 2012-2013).

Rajae devoted the first part of her career to strengthen Public Health Laboratory Services in Morocco and setting up several national and WHO reference laboratories at the NIH (HIV, Poliomyelitis and enterovirus, Influenza, measles and rubella, hepatitis). She established the Influenza Surveillance Program and concluded a Cooperative Agreement with the Centers for Diseases Control and Prevention-USA (2007-2016) to strengthen it. She has conducted many research projects and led international collaborative studies in different areas with the financial and/or the technical support of several international organizations and institutions. She has over 70 publications in peer reviewed journals.   As Director of the National Institute of Hygiene, Pr El Aouad’ focus was on institutional strengthening, research capacity building and translation of research into action, public policies and practices.  She is a strong advocate of the use of operational research and evidence based planning to support disease control programs implementation.  

Rajae  has served on several international scientific committees including the Steering Committee of the Doctoral program in Global Health,  Institute of Global Health, Geneva university (2014-Present):the Scientific and Technical Advisory Committee for African Network for Drugs and innovation (2014-present).:the WHO Consultative Expert Working Group (CEWG) on Research and Development: Financing and Coordination (2011-2012). :the Pandemic Influenza Preparedness Advisory Group for the WHO Director in October (2011-2012). :the WHO Scientific and Technical Advisory Group (STAG) for Global Influenza Programme (2008-2013). :Recently She was appointed as::Member of the Committee on Improving Scientific Input to Global Policymaking: Strategies for Attaining the Sustainable Development Goals (August 2016-June 2019).:Member of the Scientific Committee of the IAP for Health Conference on “Promoting Health” to be held in Beijing on September 2016:Observer to the One Health Platform representing the IAP for Health (2015-Present). She has built a solid network of reputable partners among world-class universities, public health institutions, and national and international NGOs. She concluded Technical and Scientific Agreements with several national and International Health research institutions. National Institutes of Health, Bethesda-USA, University Tor Vergata, Rome-Italy and the University Federico II / Napoli-Italy, the National Center of Hygiene, Mauritania, and the Al Akhawayn University, Morocco.

National Academy of Science and Technology,  Philippines

Dr. Carmencita D. Padilla MD, MAHPS
Dr Padilla is Professor of Pediatrics at the College of Medicine, University of the Philippines  (UP) Manila. She concurrently holds several key positions in the country: Executive Director of the Philippine Genome Center, UP System; Director of the Newborn Screening Reference Center – National Institutes of Health (NIH) Philippines, UP Manila; and Interim Director, Institute of Health Innovation and Translational Medicine of the Philippine California Advanced Research Institutes, Commission on Higher Education. Dr Padilla has been a recipient of numerous awards. On October 2013, she was chosen one of the 100 Most Influential Filipina Women in the World given by the US based Female Women’s Network.  Among her other recent national awards are:  Dr. Paulo C. Campos Award for Medical Research by the Philippine Association for the Advancement of Science, Inc. (PHILAAS) (2013); Most Outstanding Pediatrician given by the Philippine Pediatric Society (2013); Outstanding Science Administrator Award (2012);  Outstanding Health Research Award (2010) given by the Philippine Council for Health Research and Development (PCHRD) – Department of Science and Technology (DOST); Best Mentor in Health Research Award – National Capital Region (2009); Outstanding Filipino Physician given by JCI Senate of the Philippines and DOH in 2007.
Dr. Padilla has more than 100 publications (original articles, chapters in textbook and non-texbooks, training modules, etc).  In the area of policy making, she is responsible for crafting the Newborn Screening Act of 2004.  She is now lobbying for another bill entitled “Rare Diseases Act of the Philippines” .
Dr Padilla is a graduate of BS Pre-Medicine in UP Diliman cum laude (1976) and BS Medicine in UP College of Medicine, UP Manila (1981); MA in Health Policy Studies at the College of Public Health, UP Manila (2005). She took pediatric residency at the Philippine General Hospital and pursued a fellowship in Clinical Genetics at the Royal Alexandra Hospital for Children, Sydney, Australia.
Recognizing her varied contributions to the academic growth of genetics in the Philippines, she was conferred Academician of the National Academy of Science and Technology in 2008.

Academy of Science of Souh Africa (ASSAf)

Dr. William Pick is Professor Emeritus at the University of the Witwatersrand in South Africa, where he was the founding head of the School of Public Health. He is also Honorary Professor at the University of Cape Town, South Africa, where, after commencing his medical studies as a sixteen-year-old, he was one of the youngest graduates in medicine. In addition he holds the position of Extraordinary Professor at the University of Stellenbosch. He was elected Fellow of the Royal Society of Medicine in 1996 after having been elected a Fellow of the Royal Society of Tropical Medicine and Hygiene a few years earlier.
His work in Public Health included a Fellowship, and later a Visiting Fellowship, in International Health at Harvard University, where he participated in teaching on Urban Health. This was reflective of his interest in urbanisation and health. He also served as temporary advisor to the World Health Organisation on occasion.
In South Africa he served as the Chairperson of the Epidemiology Society of Southern Africa, and later as Chairperson of the Public Health Association of South Africa. He was awarded the Public Health Innovation and Leadership Award for Lifetime Achievement by the Public Health Association of South Africa in 2014.
He served as interim President of the South African Medical Research Council from 2003 to 2005 and served on numerous national boards and committees, which included the Health Professions Council of South Africa, the South African Health Systems Trust, the Council of the Colleges of Medicine of South Africa, where he had served as honorary secretary of the Faculty of Community Health some years earlier. He also served as the Chairperson of the Council for Medical Schemes, the national regulator of health insurance in South Africa, for six years and the Board of the South African Medical Research Council for close to nine years.
In 1994 he chaired the first post-apartheid ministerial Committee on Human Resources for Health in South Africa and in 2000 led the task team that developed a National Strategy for Human Resources for Health in South Africa.
He has produced over 100 publications in the form of journal articles, books, book chapters and monographs, which included ground-breaking work on the health of women in the urban informal sector in South Africa. He has served on a number of editorial boards and has supervised numerous doctoral and masters students.
In 2012 he received a gold medal from the University of the Witwatersrand in recognition of exceptional service and was the recipient of the President of the Convocation Medal at the University of Cape Town in 2014 in recognition of his distinguished leadership in Public Health and his work devoted to improving healthcare for all South Africans.

Swiss Academy of Medical Sciences

Prof. Thomas Zeltner
Thomas Zeltner is born in Bern (Switzerland) in 1947. He graduated with an MD and a Master’s degree in Law from the University of Bern. He is a 2010 Fellow of the Harvard Advanced Leadership Initiative. He holds a specialist degree in human pathology and forensic medicine.
He is board member of the Swiss Academies of Arts and Sciences and honorary member of the Swiss Academy of Medical Sciences. Since 1992 he has been Professor of Public Health at the University of Berne and is a Visiting Scientist at the Harvard School of Public Health (Boston). He chairs the Advisory Board of the Global Health Programme at the Graduate Institute in Geneva.
He currently serves as Special Envoy of the World Health Organization (WHO). In this capacity he advises the Director General of WHO Margaret Chan in critical areas of the current reform of this UN agency.
He is Co-Founder of the Global Patient Safety Forum, a convening organization of the world leading patient safety organizations and is Managing Editor of the Journal of Patient Safety. He is member of the Global Agenda Council on Digital Health of the World Economic Forum (WEF). He is also President of the Swiss Blood Transfusion and Stem Cell Centre of the Swiss Red Cross, the organization responsible for securing the supply of blood and blood stem cells in Switzerland
From 1991 to 2009 Thomas Zeltner has been the Director-General of the Federal Office of Public Health of Switzerland, the National Health and Public Health Authority, and Secretary of State for Health of Switzerland. In this capacity he regularly represented Switzerland at the World Health Assemblies (1991-2009). He was a member and Vice-President of the Executive Board of the World Health Organization (1999-2002).As Director-General of the Federal Office of Public Health of Switzerland he was a key actor in Swiss health policy and instrumental in promoting health promotion and disease prevention. He has presided over changes to transform the regulated market model of the Swiss health care sector into a more value and consumer driven health care system.
Prior to these functions Thomas Zeltner was head of the Medical Services at the University Hospital in Bern (Switzerland) and held various academic positions at the Medical Faculty of the University of Bern and at the Harvard School of Public Health in Boston (USA).
Academy of Medical Sciences, UK

Professor George Griffin BSc PhD FRCP (Lon, I) FMedSciProfessor George Griffin  is Professor of Medicine and Infectious Diseases at St. George’s, University of London; and Honorary Consultant Physician St. George’s Hospital. Professor Griffin developed and leads the Centre for Infection, which is internationally renowned for academic excellence, clinical medicine and postgraduate training. At St George’s Hospital, Professor Griffin continues acute inpatient and outpatient care, and is a practicing Consultant Physician, receiving local, national and international referrals. He also chairs a Serious Incident Committee across clinical disciplines.
Since 2004, Professor Griffin has chaired the Government Advisory Committee on Dangerous Pathogens (Department of Health, DEFRA and Health and Safety Executive) and was previously an advisor to the House of Lords Committee (Fighting Infection, 2007) and the Callaghan Committee (Foot and Mouth outbreak, 2008).  The Griffin Report was published in 2005 on containment level 4 facilities in the UK and Professor Griffin chaired the Review which will become the Framework for Common Set of Containment Regulations (2010) for human and animal pathogens.  In addition, he chaired the HPA Review of the E. Coli 0157 outbreak 2009, which has advised on future management and regulation of this devastating infection.  Professor Griffin was a clinical advisor to the Independent C. difficile Public Inquiry (2010), sponsored by Northern Ireland Department of Health and the Vale of Leven C.difficile public enquiry (2012). He is Chair of the Association of Clinical Professors of Medicine and is on the Editorial Board of Medicine.
Professor Griffin is Foreign Secretary of the Academy of Medical Sciences and has a strong clinical and academic international presence in developed (USA) and developing countries (Ecuador, Ghana, Gambia, India). He has given invited lectures in USA, India, South Asia, Sri Lanka, Nepal.  He is Visiting Senior Fellow in the Vaccine Research Institute, NIH, Bethesda and member of the Wellcome-India Alliance Committee.  Professor Griffin is a founder Fellow of the Academy of Medical Sciences and was elected as a distinguished Fellow of the Royal College of Physicians of Ireland in 2009. He chairs the Irish Health Board Research Committee, awarding grants for translational research.
Professor Griffin chairs the Scientific Advisory Board of the major Bill and Melinda Gates Foundation Grant to the University of Baltimore investigating the causes and potential treatments of enteric disease in developing countries. He is also am a member of the Gates Foundation International Strategy Committee defining research strategy in enteric diseases (2012-2022).

National Academy of Medicine (US)
Dr. Margaret Hamburg
Margaret A. Hamburg, M.D. is the former Commissioner of the U.S. Food and Drug Administration, having stepped down from that role in April 2015 after almost six years of ser-vice.Dr. Hamburg earned her B.A. from Harvard College, her M.D. from Harvard Medical School and completed her medical residency at Weill Cornell Medical Center
In 1991, Dr. Hamburg was named Commissioner of the New York City Department of Health. During her six-year tenure there, she implemented rigorous public health initiatives that tackled the city’s most pressing crises head-on — including improved services for women and children, an internationally recognized Tuberculosis control program, a needle-exchange program to combat HIV transmission, and the nation’s first public health bio-terrorism defense program.   
In 1997, President Clinton named Dr. Hamburg Assistant Secretary for Planning and Evaluation in the U.S. Department of Health and Human Services. She later became founding Vice President for Biological Programs at the Nuclear Threat Initiative, a foundation dedicated to reducing the threat to public safety from nuclear, chemical, and biological weapons.In March 2009,
President Obama nominated Dr. Hamburg for the post of FDA Commis-sioner. In that role, Dr. Hamburg emphasized the critical need for innovation in meeting medical care and public health needs. As Commissioner, she provided leadership on many groundbreak-ing activities, including implementation of new authorities to regulate tobacco products, new leg-islation designed to transform our nation’s food safety system to one based on prevention rather than simply responding when outbreaks occur,  and modernization of the system for the evalua-tion and approval of medical products.
Dr. Hamburg is a Fellow of the American Association for the Advancement of Science and the American College of Physicians, as well as a member of the Council on Foreign Relations and the Institute of Medicine, National Academy of Sciences, where she serves as Foreign Secretary